Asia Pacific Inhaled Nitric Oxide Market is valued approximately at USD 325.18 million in 2023 and is anticipated to grow with a healthy growth rate of more than 8.88% over the forecast period 2024-2032. Inhaled nitric oxide (iNO) is a therapeutic gas in medicine used to enhance oxygenation in individuals experiencing specific respiratory challenges. This gas acts by dilating blood vessels within the lungs, facilitating increased blood flow to regions crucial for efficient oxygen exchange. Nitric oxide is a naturally occurring molecule in the body, contributing to vasodilation and blood pressure regulation. iNO targets blood vessels surrounding oxygen-rich areas in the lungs, promoting relaxation and heightened blood flow to facilitate optimal oxygen uptake by red blood cells. This targeted action is essential in treating conditions such as neonatal respiratory treatment, chronic obstructive pulmonary disease, acute respiratory distress syndrome, others. Accordingly, iNO plays a vital role in managing vascular and oxygenation issues, especially in neonatal and critical care scenarios. The favorable government initiatives and regulatory framework is a key trend that is supporting the growth of the Asia Pacific Inhaled Nitric Oxide Market. The broad acceptance of inoculation with nitric oxide (iNO) in respiratory diseases is aided by favorable regulatory frameworks and approvals throughout the Asia-Pacific region. The safe and proper use of iNO in clinical settings is ensured by well-defined norms and regulations.

The growing prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and neonatal hypoxic respiratory failure across various parts of Asia-Pacific is acting as a catalyzing factor for the market demand at a substantial rate. According to the National Institutes of Health (NIH) case study published in June 2021, In the Asia-Pacific region, the prevalence rates of Chronic Obstructive Pulmonary Disease (COPD) vary across different countries. For instance, in Australia, the estimated COPD prevalence stands at 14.5%, while in China, it ranges from 4.4% to 16.7%. In Indonesia, the COPD prevalence is reported at 5.6%. Regarding Air Flow Limitation (FEV1/FVC < 70%), Japan recorded a prevalence rate of 10.9%, with COPD (excluding asthmatics) at 8.6%. In Korea, the COPD prevalence is 13.4%, followed by 4.7% in Malaysia, and 5.4% to 6.1% in Taiwan. Thailand has a COPD prevalence ranging from 3.7% to 6.8%, while the Philippines' rates vary from 3.5% to 20.8%. Lastly, Vietnam reports a COPD prevalence of 6.7%. These diverse prevalence rates reflect the varying degrees of COPD burden across the Asia-Pacific countries. Additionally, the increasing pediatric population, rise in healthcare expenditure, as well as growing medical tourism in the region further fuels the demand for advanced medical treatments, which is accelerating the growth of the Asia Pacific Inhaled Nitric Oxide Market. Moreover, developments in iNO delivery systems and technologies make treatment more accessible and efficient in the Asia-Pacific region. Portable iNO devices, improved monitoring capabilities, and optimized dosing regimens enhance the effectiveness of iNO therapy. However, stringent application norms across various regions, along with high costs incurred with the procedure is expected to hinder the market growth between 2022 and 2032.

The key countries considered for the Asia Pacific Inhaled Nitric Oxide Market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China was accounted as the largest regional market with the highest number of market shares. The rising prevalence of respiratory disorders such as COPD and asthma, coupled with advancements in healthcare infrastructure and technology, fuels the demand for effective treatments such as iNO. Increased awareness and education among healthcare providers and patients, along with government support and subsidies, contribute to the market's growth. Whereas, the market in India, on the other hand, is expected to develop at the fastest rate over the forecast period.

Major market player included in this report are:
Chengdu Taiyu Industrial Gases Co., Ltd. (China)
Sichuan Salman Chemical Products Co., Ltd (China)
Nippon Sanso Holdings Corporation (Japan)
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10
The detailed segments and sub-segment of the market are explained below:
By Application
Neonatal Respiratory Treatment
Chronic Obstructive Pulmonary Disease
Acute Respiratory Distress Syndrome
Others
By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.